BridgeBio Oncology Therapeutics appears to be in a critical phase of its lifecycle, with zero revenue and R&D spending surging 271% year-over-year to $49.2M in Q2 2026, indicating a major pipeline investment push. The primary risk is a severe funding runway mi...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 11, 2026 | -$0.71-24.8% vs -$0.56 | — vs — |
Q3 2026 Jun 4, 2026 | -$0.53-2.8% vs -$0.51 | — vs — |
Q2 2026 May 12, 2026 | -$0.48+6.2% vs -$0.51 | — vs — |
Q2 2026 Mar 5, 2026 | -$0.49+22.6% vs -$0.63 | — vs — |
BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new clinical data for KRASG12C inhibitor BBO-8520 and the strategic prioritization of (i) BBO-8520 in combination with checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced non-small cell lung cancer (NSCLC) patients and (ii) BBO-11818 and BBO-10203 combinations in KRAS-mutant cancers.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026.
Benchmark BBOT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BridgeBio Oncology Therapeutics Inc. (BBOT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.16 | $333.25M | -0.97 | — | — | -44.7% | — | |
| $65.71 | $12.87B | -17.34 | 126.26% | -100.64% | — | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — | |
| $4.92 | $199.75M | 4.03 | 55.25% | 45.97% | 10.97% | — | |
| $190.74 | $40.55B | -32.06 | — | — | -96.44% | — | |
| $341.75 | $10.07B | 49.96 | 33.94% | 54.82% | 19.34% | — |
BridgeBio Oncology Therapeutics Inc. (BBOT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BridgeBio Oncology Therapeutics Inc. (BBOT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Jun 22, 2026·SEC
May 12, 2026·SEC
Get notified when BBOT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BridgeBio Oncology Therapeutics Inc. (BBOT) stock FAQ — growth, dividends, profitability & financials explained
BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $182.1M for fiscal year 2025.
BridgeBio Oncology Therapeutics Inc. (BBOT) has a return on equity (ROE) of -44.7%. Negative ROE indicates the company is unprofitable.
BridgeBio Oncology Therapeutics Inc. (BBOT) had negative free cash flow of $193.8M in fiscal year 2025, likely due to heavy capital investments.
